Basit öğe kaydını göster

dc.contributor.authorTemel, Mustafa Kemal
dc.date.accessioned2021-03-06T09:42:18Z
dc.date.available2021-03-06T09:42:18Z
dc.date.issued2015
dc.identifier.citationTemel M. K. , "The development of cytotoxic chemotherapeutics in the twentieth century", TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, cilt.30, ss.96-108, 2015
dc.identifier.othervv_1032021
dc.identifier.otherav_e6c0b14a-74ef-4eea-bc06-e992c9e1f43f
dc.identifier.urihttp://hdl.handle.net/20.500.12627/151780
dc.identifier.urihttps://doi.org/10.5505/tjoncol.2015.1151
dc.description.abstractAlthough medicines have been obtained from natural products for millennia, extensive systematic studies to obtain anticancer agents through isolation from natural sources or through synthesis in the laboratory were attempted in the twentieth century. The same period also saw the development of animal models through which in vivo preclinical research could be conducted to examine the anticancer potential of chemicals, in addition to in vitro research. In the 1940s the era of modern cancer chemotherapy started with the introduction of the first classical chemotherapeutics; the first alkylating agents were obtained in the early 1940s and the first antimetabolites toward the end of the decade. In the 1950s scientists ventured out of the laboratory to discover natural products with anticancer potential. Since microorganisms, sessile terrestrial plants and marine invertebrates have evolved a large number of chemical defense mechanisms, it has been argued that some substances out of these might show anticancer activity. Tens of thousands of natural products derived from these organisms have been screened for anticancer activity primarily by the US since the 1950s. Vinca alkaloids introduced in the 1960s, anticancer antibiotics in the 1970s and taxanes in the 1990s are examples of the encouraging outcomes. In addition to local interventions such as surgery and radiotherapy, cancer chemotherapy based upon these therapeutic agents is available in medicine today as a systemic modality in the treatment of the disease.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleThe development of cytotoxic chemotherapeutics in the twentieth century
dc.typeMakale
dc.relation.journalTURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume30
dc.identifier.issue2
dc.identifier.startpage96
dc.identifier.endpage108
dc.contributor.firstauthorID219126


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster